OLD: Cafepharma Detail Piece Daily Pharma Headlines Archive for February, 2011

IMPORTANT: On Sunday, April 22, we send out an email with some important changes to our newsletter service. Please make sure you read this email, or the details on our our newsletter page, as our newsletter service changes will be taking effect on Monday, May 7, 2018.  On that date, your current newsletter subscription will end if you have not subscribed under our new plan. 

Click a link below to view the mailing archive as if it had been sent to you. 2011-02-26 12:00 BioSante Pharma completes enrollment in LibiGel phase III efficacy trial and more... 2011-02-26 00:00 J&J will pay CEO $1.9 million salary for 2011; Johnson & Johnson slashes CEO bonus after year of product recalls and more... 2011-02-25 12:00 Abbott Laboratories Passes This Key Test and more... 2011-02-25 00:00 Is Novartis the Perfect Stock? and more... 2011-02-24 12:00 Pozen migraine drug fails to get patent extension and more... 2011-02-24 00:00 Takeda seeks U.S. approval of hypertension drug and more... 2011-02-23 12:00 New Senate Legislation May Impede Voluntary Self-Enforcement by Companies Regulated by FDA and more... 2011-02-23 00:00 Regeneron: A Well-Executed Strategy and more... 2011-02-22 12:00 Just How Likely Is It That Diabetes Drugmaker Amylin Could Go Bankrupt? and more... 2011-02-21 12:00 Celgene: Biotech Baron or Barren Biotech? and more... 2011-02-21 00:00 China Biotech Week in Review: China Encourages Private Entities to Invest in Healthcare and more... 2011-02-20 00:00 Biotech industry says cuts will stifle and more... 2011-02-19 12:00 Tysabri reports 10 more brain disease cases and more... 2011-02-19 00:00 Top Biotech Takeout Targets in 2011 and more... 2011-02-18 12:00 Biotech Mailbag: BIO CEO Wrap and more... 2011-02-18 00:00 Sanofi/Genzyme: The Hard Work Begins and more... 2011-02-17 12:00 Biotechs Ready To Roll and more... 2011-02-17 00:00 FDA Likely to Approve Spectrum Pharma's Cancer Drug After Second Look and more... 2011-02-16 12:00 Eli Lilly: Plenty of Talk, Now Time for Results and more... 2011-02-16 00:00 Sanofi's Buy of Genzyme Imminent: Report and more... 2011-02-15 12:00 Who will blink in Genzyme, Sanofi price talks? and more... 2011-02-15 00:00 After the Earnings, What's in the Works For Vanda? and more... 2011-02-13 12:00 Is It Worth Buying the MannKind Dip? and more... 2011-02-13 00:00 Soliris Continues to Drive Growth as Alexion Adds to Its Pipeline and more... 2011-02-12 00:00 Opko Health seeks $250M offering and more... 2011-02-11 12:00 Gilead refiles for approval of HIV drug and more... 2011-02-10 12:00 Nymox: Another Look at Enlarged-Prostate Drug and more... 2011-02-10 00:00 Amgen Pushes Ahead With "Son of Dmab" for Treating Bones and more... 2011-02-09 12:00 Teva Risks Disappointments as Top Drug Faces Threats and more... 2011-02-09 00:00 Ready for the Biotech Century: Where's the Smart Money Going? and more... 2011-02-08 12:00 Technical Analysis: Rexahn Pharmaceuticals and more... 2011-02-08 00:00 Zibotentan Stopped, Long Live Provenge (for Now) and more... 2011-02-07 12:00 Is Orexigen Therapeutics Still a Good Buy? and more... 2011-02-06 00:00 "Big Pharma has Created Wealth, While Biotech has Destroyed Wealth" 2011-02-05 12:00 Pfizer & Takeda enter co-promotion agreements for rheumatoid arthritis products in Japan and more... 2011-02-04 12:00 Sanofi Better Smart as Options Lower GenzymeâÔö£é?öé??Ôö£é?ö?ñós Price: Real M&A and more... 2011-02-04 00:00 Get Ready for Merck's Bumpy Ride and more... 2011-02-03 12:00 FDA Rejection Would Take Isis Stock Down and more... 2011-02-03 00:00 Mannkind Shares Popped: What You Need to Know and more... 2011-02-02 12:00 Four Pharma Stocks With Appealing Value, Dividend Yield and more... 2011-02-02 00:00 Generic Risk Looms over Endo Pharma and more... 2011-02-01 12:00 Let It Snow, Let It Snow, I-P-O and more... 2011-02-01 00:00 5 Drugmakers Headed Back to the Drawing Board and more...   << Archive Index • Subscribe >>   Subscription preference center Archive Powered by FeedBlitz

Contact Us Past Issues Unsubscribe